In This Section

Program: Thursday, July 23

Tuesday, July 21 Wednesday, July 22 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Thursday, July 23

Thursday, July 23

Networking Breakfast

7-8 am | Independence Ballroom West

Keynote Lecture

8-9 am | Grand Ballroom

  • 8:05 a.m. | Keynote Lecture
    William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
  • 8:45 a.m. | Q&A   

Break

9-9:15 a.m. | Grand Ballroom Prefunction

Plenary Sessions 3-4

9:15-11:15 a.m.

Plenary Session 3: AI in Oncology: Facts and Hopes

Grand Ballroom
Session Chair: Sarah Skerratt, Chief Research Officer, Isomorphic Labs, London, United Kingdom

  • 9:20 a.m. | Sarah Skerratt
  • 9:50 a.m. | Jorge Reis-Filho, AstraZeneca, New York, New York
  • 10:20 a.m. | Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • 10:50 a.m. | Panel Discussion

Plenary Session 4: From RAS Inhibitors to RAS Degraders

Constitution Ballroom A
Session Chair: Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York

  • 9:20 a.m. | Development of KRAS G12D degraders
    Kathryn Smith, Arvinas, New Haven, Connecticut
  • 9:40a.m. | Speaker to be announced
  • 10 a.m. | Novel molecular glue degraders to target KRAS mutants
    Anita C. Bellail, HB Therapeutics, Indianapolis, Indiana
  • 10:20 a.m. | Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
  • 10:50 a.m. | Panel Discussion

Break

11:15-11:30 a.m.

Concurrent Roundtables 1-2

11:30 a.m.-12:30 p.m.

Roundtable 1: Policy

Constitution Ballroom A

  • 11:30 a.m. | Introductions
  • 11:40 a.m. | Discussion
  • 12:15 p.m. | Q&A

Roundtable 2: Accelerating Investigator-Initiated Clinical Trials with Team Science

Constitution Ballroom B
Moderator: Elizabeth A. Jaffee, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

  • Panelists:|
    Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
    Sarah Goldberg, Yale University, New Haven, Connecticut
    Anthony Joshua, Garvan Institute of Medical Research, Sydney, NSW, Australia
    Anirban Maitra, NYU Langone Health Perlmutter Cancer Center, New York, New York
    Additional panelists to be announced
  • 11:30 a.m. | Introductions
  • 11:40 a.m. | Discussion
  • 12:15 p.m. | Q&A

Lunch on Own

12:30-2:45 p.m.

Start-Up Shark Tank 1

3-4:30 p.m.

Break

4:30-4:45 p.m. | Grand Ballroom Prefunction

Drugging the Surfacesome Sessions 1-3

4:45-6:15 p.m.

Drugging the Surfacesome 1: Drug conjugates for solid tumors – Choosing the Right Modality for the Right Target

Grand Ballroom
Session Chair: Raffaele Colombo, Zymeworks Inc., Vancouver, British Columbia, Canada

  • 4:50 p.m. | Advancements in small molecule drug conjugates with cytotoxic payloads and radioligands
    Dario Neri, ETH Zurich, Zurich, Switzerland
  • 5:10 p.m. | Radioconjugated antibodies and antibody fragments as precision therapeutics
    Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
  • 5:30 p.m. | Optimizing payload delivery: Lessons from ADC mechanisms and clinical translation
    Jamie Rich, Zymeworks Inc., Vancouver, British Columbia, Canada
  • 5:50 p.m. | Molecular imaging in drug development and as a biomarker to guide treatment decisions: What we learn from imaging antibody-based agentsin patients
    Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands

Drugging the Surfacesome 2: Multispecifics

Constitution Ballroom A
Session Chair: Daniel S. Chen, Synthetic Design Lab, San Carlos, California

  • 4:50 p.m. | Multispecific protein expression and proximity therapeutics
    Pamela Holland, InduPro, Seattle, Washington
  • 5:10 p.m. | Multifunctional multivalent multispecific therapeutics
    Daniel S. Chen
  • 5:30 p.m. | Djuro Karanovic, AstraZeneca, Gaithersburg, Maryland
  • 5:50 p.m. | Panel Discussion

Drugging the Surfacesome 3: Radionucleotides

Constitution Ballroom B
Session Chair: H. Charles Manning, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 4:50 p.m. | Speaker to be announced
  • 5:10 p.m. | Speaker to be announced
  • 5:30 p.m. | Speaker to be announced
  • 5:50 p.m. | Panel Discussion

Poster Session B / Reception

6:15-8:45 p.m. | Back Bay Ballroom

Evening off / Dinner on own

8:45 p.m.